Abstract:ABSTRACT Genetically-engineered immune cell therapies have been in development for decades 1–3 and recently have proven effective to treat some types of cancer 4 . CRISPR-based genome editing methods, enabling more flexible and targeted sequence integrations than viral transduction, have the potential to extend the clinical utility of cell therapies 5,6 . Realization of this potential depends on improved knowledge of how coding and non-coding sites throughout the genome can be modified efficiently and on improved methods to discover novel synthetic DNA sequences that can be introduced at targeted sites to enhance critical immune cell functions. Here, we developed improved guidelines for non-viral genome targeting in human T cells and a pooled discovery platform to identify synthetic genome modifications that enhance therapeutically-relevant cell functions. We demonstrated the breadth of targetable genomic loci by performing large knock-ins at 91 different genomic sites in primary human T cells, and established the power of flexible genome targeting by generating cells with Genetically Engineered Endogenous Proteins (GEEPs) that seamlessly integrate synthetic and endogenous genetic elements to alter signaling input, output, or regulatory control of genes encoding key immune receptors. Motivated by success in introducing synthetic circuits into endogenous sites, we then developed a platform to facilitate discovery of novel multi-gene sequences that reprogram both T cell specificity and function. We knocked in barcoded pools of large DNA sequences encoding polycistronic gene programs. High-throughput pooled screening of targeted knock-ins to the endogenous T cell receptor (TCR) locus revealed a transcriptional regulator and novel protein chimeras that combined with a new TCR specificity to enhance T cell responses in the presence of suppressive conditions in vitro and in vivo . Overall, these pre-clinical studies provide flexible tools to discover complex synthetic gene programs that can be written into targeted genome sites to generate more effective therapeutic cells.

Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing

T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System

CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy

Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits

An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer

Non-viral delivery of RNA for therapeutic T cell engineering

Targeting Precision in Cancer Immunotherapy: Naturally-Occurring Antigen-Specific TCR Discovery with Single-Cell Sequencing

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells

A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells

Orthotopic T-cell receptor replacement in primary human T cells using CRISPR-Cas9-mediated homology-directed repair

Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner

Rapid Cloning, Expression, And Functional Characterization Of Paired Alpha Beta And Gamma Delta T-Cell Receptor Chains From Single-Cell Analysis

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons

A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells

T-Cell-Based Platform for Functional Screening of T-Cell Receptors Identified in Single-Cell RNA Sequencing Data Sets of Tumor-Infiltrating T-Cells

Rapid identification of tumor-reactive T-cell receptors by RNA preamplification-based single-cell sequencing.

Optimized two‐step electroporation process to achieve efficient nonviral‐mediated gene insertion into primary T cells

Generation of T cells with reduced off-target cross-reactivities by engineering co-signalling receptors

The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies